Laboratório de Microbiologia Molecular e Clínica, Universidade São Francisco, Bragança Paulista, Brazil.
College of Medicine and Public Health. Flinders University, Adelaide, South Australia, Australia.
Vaccine. 2021 Jun 16;39(27):3626-3632. doi: 10.1016/j.vaccine.2021.04.068. Epub 2021 May 25.
The implementation of polysaccharide-based vaccines has massively reduced the incidence of invasive pneumococcal diseases. However, there is great concern regarding serotype replacement and the increase in antibiotic resistant strains expressing non-vaccine capsular types. In addition, conjugate vaccines have high production costs, a limiting factor for their implementation in mass immunization programs in developing countries. These limitations have prompted the development of novel vaccine strategies for prevention of Streptococcus pneumoniae infections. The use of conserved pneumococcal antigens such as recombinant proteins or protein fragments presents an interesting serotype-independent alternative. Pht is a family of surface-exposed proteins which have been evaluated as potential vaccine candidates with encouraging results. The present work investigated the immune responses elicited by subcutaneous immunization of mice with the polyhistidine triad protein D (PhtD) and its amino and carboxyl terminal fragments. The proteins were immunogenic and protective against pneumococcal sepsis in mice. Antibodies raised against PhtD increased complement C3b deposition on the pneumococcal surface, mainly mediated by the alternative pathway. Sera from mice immunized with PhtD and PhtD_Cter promoted an increase in bacterial uptake by mouse phagocytes. The interaction of PhtD with the complement system regulator factor H was investigated in silico and in vitro by ELISA and western blot, confirming PhtD as a factor-H binding protein. Our results support the inclusion of PhtD and more specifically, its C-terminal fragment in a multicomponent serotype independent vaccine and suggests a role for the complement system in PhtD-mediated protection.
多糖疫苗的实施大大降低了侵袭性肺炎球菌病的发病率。然而,人们非常关注血清型替代和表达非疫苗荚膜型的抗生素耐药菌株的增加。此外,结合疫苗的生产成本很高,这限制了它们在发展中国家大规模免疫接种计划中的实施。这些限制促使人们开发了预防肺炎链球菌感染的新型疫苗策略。使用保守的肺炎球菌抗原,如重组蛋白或蛋白片段,是一种有趣的、与血清型无关的替代方法。Pht 是一组表面暴露蛋白,已被评估为具有令人鼓舞结果的潜在疫苗候选物。本工作研究了用多组氨酸三联体蛋白 D(PhtD)及其氨基和羧基末端片段皮下免疫小鼠引起的免疫反应。这些蛋白具有免疫原性,并能保护小鼠免受肺炎球菌败血症的侵害。针对 PhtD 产生的抗体增加了肺炎球菌表面补体 C3b 的沉积,主要通过替代途径介导。用 PhtD 和 PhtD_Cter 免疫的小鼠血清促进了吞噬细胞对细菌的摄取增加。通过 ELISA 和 Western blot 在体内和体外研究了 PhtD 与补体系统调节剂因子 H 的相互作用,证实 PhtD 是因子 H 结合蛋白。我们的结果支持将 PhtD 及其更具体地说,其 C 末端片段纳入多组分、与血清型无关的疫苗中,并表明补体系统在 PhtD 介导的保护中发挥作用。